Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.54 |
| ▸ | CKS1B | P61024 | 2/20 | 0.52 |
| ▸ | SKP1 | P63208 | 2/20 | 0.52 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901264 | 1.00 | GPR119 (0.54) | GPR119CKS1BSKP1SKP2LRRK2 | |
| SCHEMBL11963375 | 0.95 | CKS1B (0.55) | GPR119CKS1BSKP1SKP2LRRK2 | |
| SCHEMBL29132224 | 0.90 | GPR119 (0.53) | GPR119CKS1BSKP1SKP2LRRK2 | |
| SCHEMBL15228419 | 0.87 | GPR119 (0.56) | GPR119CKS1BSKP1SKP2LRRK2 | |
| SCHEMBL29132048 | 0.86 | GPR119 (0.57) | GPR119 | |
| SCHEMBL24671505 | 0.86 | GPR119 (0.52) | GPR119LRRK2 | |
| SCHEMBL29132280 | 0.86 | GPR119 (0.52) | GPR119CKS1BSKP1SKP2LRRK2 | |
| SCHEMBL30066214 | 0.86 | GPR119 (0.52) | GPR119LRRK2 | |
| SCHEMBL113805 | 0.86 | GPR119 (0.55) | GPR119CKS1BSKP1SKP2LRRK2 | |
| SCHEMBL29132285 | 0.85 | GPR119 (0.55) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| CN-120040416-A | Piperazine amide skeleton compound and application thereof | 中国药科大学 | 2025-05-27 | — | — | CN | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |